Anthony Lee, MD
Neurology · Kalamazoo, MINPI 1801060397
Payments from drug & device makers
Across 45 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$180
- Teva Pharmaceuticals USA, Inc.$134
- Bristol Myers Squibb$74
- Supernus Pharmaceuticals, Inc.$73
- Abbott$62
- Lundbeck LLC$60
- plus $528 from 17 others
What the payments were for
- Speaking & faculty fees$212%
- Food & beverage$1,07196%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $180 |
| Teva Pharmaceuticals USA, Inc. | 6 | $134 |
| Bristol Myers Squibb | 3 | $74 |
| Supernus Pharmaceuticals, Inc. | 5 | $73 |
| Abbott | 1 | $62 |
| Lundbeck LLC | 2 | $60 |
| Sunovion Pharmaceuticals Inc. | 3 | $54 |
| Biogen | 2 | $51 |
| Acorda Therapeutics, Inc | 2 | $46 |
| AstraZeneca | 3 | $44 |
| Novartis | 2 | $40 |
| Genentech USA, Inc. | 2 | $36 |
| UCB, Inc. | 1 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| EMD Serono, Inc. | 2 | $28 |
| Sanofi | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| SK Life Science, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$150
How this compares
$1,112 in reported general payments places this provider in the 45th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 35 | $375,974 |
| IngrezzaValbenazine Tosylate | 18 | $200,463 |
| AubagioTeriflunomide | 13 | $192,403 |
| Teriflunomide | 38 | $182,880 |
| BetaseronInterferon Beta-1b | 18 | $168,142 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 18 | $153,170 |
| Kesimpta PenOfatumumab | 13 | $131,705 |
| MayzentSiponimod | 11 | $107,745 |
| Aimovig AutoinjectorErenumab-Aooe | 97 | $84,477 |
| Dimethyl Fumarate | 38 | $71,028 |
| NuedextaDextromethorphan Hbr/Quinidine | 40 | $48,695 |
| AptiomEslicarbazepine Acetate | 32 | $45,570 |
| Topiramate ErTopiramate | 29 | $34,386 |
| Trokendi XrTopiramate | 26 | $31,534 |
| Nurtec OdtRimegepant Sulfate | 19 | $31,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $20 | $200,46318 claims |
| SanofiAubagio | $27 | $192,40313 claims |
| NovartisMayzent | $40 | $107,74511 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $54 | $45,57032 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $73 | $31,53426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 652 neurology providers in Michigan.
Other neurology in Kalamazoo
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.